Tisotumab vedotin - Genmab/Seagen
Alternative Names: HuMax-TF; HuMax-TF-ADC; Humax®-TF-ADC; TF-011-MMAE; Tisotumab vedotin-tftv - Genmab/Seagen; TIVDAKLatest Information Update: 06 May 2024
At a glance
- Originator Genmab
- Developer Genmab; Seagen; ZAI Lab
- Class Antineoplastics; Auristatins; Drug conjugates; Immunotherapies; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cervical cancer
- Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
Most Recent Events
- 29 Apr 2024 Updated adverse events data from the phase II innovaTV 204 trial in Cervical cancer released by Genmab
- 29 Apr 2024 Updated adverse events data from the phase III InnovaTV 301 trial in Cervical cancer released by Genmab
- 29 Apr 2024 The US FDA grants full approval for sBLA for Tisotumab vedotin for Cervical cancer (Recurrent, Metastatic disease, Secon-line therapy or greater) in the US